Entrada’s shares plunged after initial dystrophin readouts for ENTR-601-44 in Duchenne muscular dystrophy came in below what investors expected. The trial met safety and tolerability, and researchers reported functional benefits including time-to-rise changes, but investors focused on dystrophin production relative to baseline. Meanwhile, Engene Therapeutics’ stock also suffered steep losses following additional interim data for detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The updates arrived ahead of further pivotal readouts, and the market response suggested that the incremental efficacy signals were not enough to offset concerns. These moves underline how early protein-expansion or disease-control metrics can quickly reshape valuation in mutation-specific oncology programs.